



August 2, 2024

To Whom It May Concern

Option Agreement for drug discovery of extracellular vesicles derived from airway epithelial cells

KYORIN Pharmaceutical Co., Ltd. (Head office: Chiyoda-ku, Tokyo, President & CEO: Yutaka Ogihara, hereafter “KYORIN” and EVerMed Inc. (Head office: Minato-ku, Tokyo, President: Naoto Matsuda, hereafter “EVerMed”) today announced that they have entered into an option agreement for drug discovery of extracellular vesicles derived from airway epithelial cells.

KYORIN secure the option to acquire the license for the development and commercialization of EM-001, which is one of drug seeds/pipeline held by EVerMed and is planned of Phase 1 study by EVerMed and the Jikei University School of Medicine.

Under the terms of the option agreement, KYORIN will make an upfront payment to EVerMed. If KYORIN exercises its option, KYORIN will additionally make milestone payments depending on the progress in the development of EM-001, as well as sales royalties depending on the sales of EM-001 after its launch to EVerMed.

EM-001 is extracellular vesicle derived from airway epithelial cells and expected to function in suppression of cell aging and fibrosis, and in normalization of traits, by transport of enclosing complex. The therapeutic effect of EM-001 has been confirmed in model animals, which gives rise to an expectation that EM-001 will be a good candidate for the treatment of respiratory diseases.

KYORIN aims to create high-value new drugs that meet medical needs under its long-term vision “Vision 110”. KYORIN will achieve continuous new drug creation through the active use of open innovation.

[Contact]

KYORIN Pharmaceutical Co., Ltd.

Corporate Planning

Tel: 03-6374-9702

EVERMed Inc.

E-mail: info@evermed.jp

[Reference]

1. About Kyorin

KYORIN aims to become a company that contributes broadly to people's health by pursuing innovation in drug discovery to strengthen drug discovery capability to create high-value new drugs that meet medical needs, accelerating its evaluation and acquisition of in-licensed products and establishing a presence in designated fields.

Trade Name: KYORIN Pharmaceutical Co., Ltd.

Location: 1-3-7 Otemachi, Chiyoda-ku, Tokyo

Foundation: December, 1923

President & CEO: Yutaka Ogihara

URL : <https://www.kyorin-pharm.co.jp/>

2. About EVERMed

EverMed Inc. is a biotech startup founded based on the research of Dr. Yu Fujita of the Department of Respiratory Medicine and Next-Generation Drug Discovery Research at the Jikei University School of Medicine (Tokyo Japan) on the use of extracellular vesicles (EVs) to treat intractable respiratory diseases.

Trade Name: EVERMed Inc.

Location: 3-25-8 Nishishinbashi, Minato-ku, Tokyo

Establishment: April, 2024

Representative Director: Naoto Matsuda

URL : <http://evermed.jp/>

3. About drug discovery of Extracellular vesicles (EVs)

EVs, including exosomes secreted from cells, is being development in the world as novel modality. Exosome derived from airway epithelial cells is expected to suppress the progression of IPF, based on research results in the Jikei University School of Medicine

*Press release: August 2, 2021, The Jikei University